IP Library › Patent Application 16446109
Patent Application
App. No. 16/446,109

METHODS AND PHARMACEUTICAL COMPOSITIONS COMPRISING A SGLT2 INHIBITOR FOR TREATING OR IMPROVING ERECTILE DYSFUNCTION

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/446,109
Abstract

The invention relates to methods for improving glycemic control and for treating erectile dysfunction in a patient diagnosed with prediabetes, type 1 diabetes mellitus, type 2 diabetes mellitus or metabolic syndrome wherein a SGLT2 inhibitor is administered to the patient. Furthermore the invention relates to a method for improving a treatment of erectile dysfunction in a male patient diagnosed with prediabetes, type 1 diabetes mellitus or type 2 diabetes mellitus characterized in that in addition to the treatment of erectile dysfunction a SGLT2 inhibitor is administered to the patient. The invention also relates a pharmaceutical composition comprising a SGLT2 inhibitor and a compounds selected from the group consisting of PDE5 inhibitors or alprostadil.

Claims (15)

1 . A method for improving glycemic control in a patient diagnosed with prediabetes, type 1 diabetes mellitus, type 2 diabetes mellitus or metabolic syndrome comprising administering a SGLT2 inhibitor to the patient, wherein the patient is a male patient diagnosed with erectile dysfunction.

2 . A method for treating erectile dysfunction in a male patient diagnosed with prediabetes, type 1 diabetes mellitus, type 2 diabetes mellitus or metabolic syndrome comprising administering a SGLT2 inhibitor to the patient.

3 . The method according to claim 1 , wherein the patient is a poor-responder or a non-responder to a treatment with a PDE5 inhibitor.

4 . The method according to claim 1 , wherein the patient is over the age of 60 years.

5 . The method according to claim 1 , wherein the patient has insufficient glycemic control despite antidiabetic treatment with one or more medicaments not including SGLT2 inhibitors.

6 . The method according to claim 1 , wherein in addition to the administration of a SGLT2 inhibitor one or more antidiabetic medicaments not belonging to the class of SGLT2 inhibitors are administered to the patient.

7 . The method according to claim 1 , wherein the SGLT2 inhibitor is empagliflozin.

8 . The method according to claim 7 , wherein empagliflozin is administered in an amount of 2.5 to 25 mg.

9 . A method for improving a treatment of erectile dysfunction in a male patient diagnosed with prediabetes, type 1 diabetes mellitus, type 2 diabetes mellitus or metabolic syndrome comprising administering a SGLT2 inhibitor to the patient in addition to the treatment of erectile dysfunction.

10 . The method according to claim 9 , wherein the treatment of erectile dysfunction comprises the administration of one or more medicaments selected from the group consisting of PDE5 inhibitors or alprostadil.

11 . The method according to claim 9 , wherein the SGLT2 inhibitor is empagliflozin.

12 . The method according to claim 11 , wherein empagliflozin is administered in an amount of 2.5 to 25 mg.

13 . A pharmaceutical composition comprising a SGLT2 inhibitor and one or more compounds selected from the group consisting of PDE5 inhibitors, apomorphin or alprostadil.

14 . The pharmaceutical composition according to claim 13 , wherein the SGLT2 inhibitor is empagliflozin.

15 . The pharmaceutical composition according to claim 13 , wherein the amount of empagliflozin is from 2.5 to 25 mg.